Pfizer of Medsafe Criminal Referral

Chuck Schooner (Account suspended) made this Official Information request to New Zealand Police

The request was refused by New Zealand Police.

From: Chuck Schooner (Account suspended)

Dear New Zealand Police,

In early 2021 circa February Medsafe approved the Pfizer vaccination for 9 months based on provisional approval with a number of conditions that they were required to meet for the provisional approval to be extended.

On 3rd November provisional approval was extended for a period of two years with Pfizer apparently being able to meet a number of conditions for this provisional approval to be extended.

To date official information act requests to Ministry of Health have failed to provide adequate documentation confirming that Pfizer have met the conditions.

At the end of December the FDA in the USA was ordered to release a number of Pfizer documents that were used in their own approval. Part of the release included a document titled

Cumulative Analysis of Post Adverse Event Records Report

This document showed in the first 90 days there were tens of thousands of very serious adverse reactions including over 1,000 people dying. This document is now available for Ministry of Health and it would be interesting to see if they already had this document prior to the vaccine approval. Given this information and the imminent roll out of this vaccine in children I ask that an immediate investigation into

- if this document was available prior to any approvals - because if it was there has either been gross misconduct, criminal negligence
- if the document was not produced by Pfizer should they be investigated
- approval panel and any conflicts
- financial dealings of the panel
- any political influence over the approval process
- financial dealings of any politicians peddling this jab

If the vaccine is rolled out in children 7-11 now that this document is available they are knowingly inflicting death and long term illnesses in children and need to investigated immediately.

I do feel sorry for any and all of the New Zealand police staff who were coerced into this vaccine or was forced to vacate their position. It appears they made the right decision and I would request NZ Police do the right thing and reinstate their roles.

Yours faithfully,

Chuck Schooner

Link to this

From: Ministerial Services
New Zealand Police

Tēnā koe Chuck

Thank you for your correspondence below.

While your request is not for official information, it has been referred to the National Criminal Investigation Group for review. They will respond to you directly.

Ngā mihi
Fiona
Ministerial Services
Police National Headquarters

-----Original Message-----
From: Chuck Schooner <[FOI #17879 email]>
Sent: Wednesday, 8 December 2021 10:06 am
To: Ministerial Services <[email address]>
Subject: [EXTERNAL] Official Information request - Pfizer of Medsafe Criminal Referral

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear New Zealand Police,

In early 2021 circa February Medsafe approved the Pfizer vaccination for 9 months based on provisional approval with a number of conditions that they were required to meet for the provisional approval to be extended.

On 3rd November provisional approval was extended for a period of two years with Pfizer apparently being able to meet a number of conditions for this provisional approval to be extended.

To date official information act requests to Ministry of Health have failed to provide adequate documentation confirming that Pfizer have met the conditions.

At the end of December the FDA in the USA was ordered to release a number of Pfizer documents that were used in their own approval. Part of the release included a document titled

Cumulative Analysis of Post Adverse Event Records Report

This document showed in the first 90 days there were tens of thousands of very serious adverse reactions including over 1,000 people dying. This document is now available for Ministry of Health and it would be interesting to see if they already had this document prior to the vaccine approval. Given this information and the imminent roll out of this vaccine in children I ask that an immediate investigation into

- if this document was available prior to any approvals - because if it was there has either been gross misconduct, criminal negligence
- if the document was not produced by Pfizer should they be investigated
- approval panel and any conflicts
- financial dealings of the panel
- any political influence over the approval process
- financial dealings of any politicians peddling this jab

If the vaccine is rolled out in children 7-11 now that this document is available they are knowingly inflicting death and long term illnesses in children and need to investigated immediately.

I do feel sorry for any and all of the New Zealand police staff who were coerced into this vaccine or was forced to vacate their position. It appears they made the right decision and I would request NZ Police do the right thing and reinstate their roles.

Yours faithfully,

Chuck Schooner

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #17879 email]

Is [New Zealand Police request email] the wrong address for Official Information requests to New Zealand Police? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

===============================================================
WARNING
The information contained in this email message is intended for the addressee only and may contain privileged information. It may also be subject to the provisions of section 50 of the Policing Act 2008, which creates an offence to have unlawful possession of Police property. If you are not the intended recipient of this message or have received this message in error, you must not peruse, use, distribute or copy this message or any of its contents.
Also note, the views expressed in this message may not necessarily reflect those of the New Zealand Police. If you have received this message in error, please email or telephone the sender immediately

hide quoted sections

Link to this

From: Ministerial Services
New Zealand Police

Tēnā koe Chuck

Further to my email earlier today, I have received further advice regarding your correspondence.

Your email does not comprise a request for information, and therefore the Official Information Act 1982 does not apply.

I am advised that your comments and views expressed in your email do not justify a criminal investigation. You may wish to direct your comments and queries to the Ministry of Health.

Ngā mihi
Fiona
Ministerial Services
Police National Headquarters

-----Original Message-----
From: Ministerial Services
Sent: Thursday, 9 December 2021 8:47 am
To: 'Chuck Schooner' <[FOI #17879 email]>
Subject: RE: [EXTERNAL] Official Information request - Pfizer of Medsafe Criminal Referral

Tēnā koe Chuck

Thank you for your correspondence below.

While your request is not for official information, it has been referred to the National Criminal Investigation Group for review. They will respond to you directly.

Ngā mihi
Fiona
Ministerial Services
Police National Headquarters

-----Original Message-----
From: Chuck Schooner <[FOI #17879 email]>
Sent: Wednesday, 8 December 2021 10:06 am
To: Ministerial Services <[email address]>
Subject: [EXTERNAL] Official Information request - Pfizer of Medsafe Criminal Referral

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear New Zealand Police,

In early 2021 circa February Medsafe approved the Pfizer vaccination for 9 months based on provisional approval with a number of conditions that they were required to meet for the provisional approval to be extended.

On 3rd November provisional approval was extended for a period of two years with Pfizer apparently being able to meet a number of conditions for this provisional approval to be extended.

To date official information act requests to Ministry of Health have failed to provide adequate documentation confirming that Pfizer have met the conditions.

At the end of December the FDA in the USA was ordered to release a number of Pfizer documents that were used in their own approval. Part of the release included a document titled

Cumulative Analysis of Post Adverse Event Records Report

This document showed in the first 90 days there were tens of thousands of very serious adverse reactions including over 1,000 people dying. This document is now available for Ministry of Health and it would be interesting to see if they already had this document prior to the vaccine approval. Given this information and the imminent roll out of this vaccine in children I ask that an immediate investigation into

- if this document was available prior to any approvals - because if it was there has either been gross misconduct, criminal negligence
- if the document was not produced by Pfizer should they be investigated
- approval panel and any conflicts
- financial dealings of the panel
- any political influence over the approval process
- financial dealings of any politicians peddling this jab

If the vaccine is rolled out in children 7-11 now that this document is available they are knowingly inflicting death and long term illnesses in children and need to investigated immediately.

I do feel sorry for any and all of the New Zealand police staff who were coerced into this vaccine or was forced to vacate their position. It appears they made the right decision and I would request NZ Police do the right thing and reinstate their roles.

Yours faithfully,

Chuck Schooner

-------------------------------------------------------------------

This is an Official Information request made via the FYI website.

Please use this email address for all replies to this request:
[FOI #17879 email]

Is [New Zealand Police request email] the wrong address for Official Information requests to New Zealand Police? If so, please contact us using this form:
https://fyi.org.nz/change_request/new?bo...

Disclaimer: This message and any reply that you make will be published on the internet. Our privacy and copyright policies:
https://fyi.org.nz/help/officers

If you find this service useful as an Official Information officer, please ask your web manager to link to us from your organisation's OIA or LGOIMA page.

-------------------------------------------------------------------

===============================================================
WARNING
The information contained in this email message is intended for the addressee only and may contain privileged information. It may also be subject to the provisions of section 50 of the Policing Act 2008, which creates an offence to have unlawful possession of Police property. If you are not the intended recipient of this message or have received this message in error, you must not peruse, use, distribute or copy this message or any of its contents.
Also note, the views expressed in this message may not necessarily reflect those of the New Zealand Police. If you have received this message in error, please email or telephone the sender immediately

hide quoted sections

Link to this

From: Chuck Schooner (Account suspended)

Dear Ministerial Services,

This was the response I was expecting and not surprising. When they sign off this vaccine for children in January which they will inevitably do you will be complicit in inflicting a generation of illness on the vulnerable. Here is a list of the SERIOUS side effects directly from the Pfizer document. Well done.

APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST
1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic
neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epileptic
aphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acute
encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic
dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute
haemorrhagic oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acute
motor axonal neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardial
infarction;Acute respiratory distress syndrome;Acute respiratory failure;Addison's
disease;Administration site thrombosis;Administration site vasculitis;Adrenal
thrombosis;Adverse event following immunisation;Ageusia;Agranulocytosis;Air
embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic
seizure;Allergic bronchopulmonary mycosis;Allergic oedema;Alloimmune
hepatitis;Alopecia areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammonia
increased;Amniotic cavity infection;Amygdalohippocampectomy;Amyloid
arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic
shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid
shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic
neuropathy;Ankylosing spondylitis;Anosmia;Antiacetylcholine receptor antibody
positive;Anti-actin antibody positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia
antibody positive;Anti-cyclic citrullinated peptide antibody positive;Anti-epithelial antibody
positive;Anti-erythrocyte antibody positive;Anti-exosome complex antibody positive;AntiGAD antibody negative;Anti-GAD antibody positive;Anti-ganglioside antibody
positive;Antigliadin antibody positive;Anti-glomerular basement membrane antibody
positive;Anti-glomerular basement membrane disease;Anti-glycyl-tRNA synthetase antibody
positive;Anti-HLA antibody test positive;Anti-IA2 antibody positive;Anti-insulin antibody
increased;Anti-insulin antibody positive;Anti-insulin receptor antibody increased;Antiinsulin receptor antibody positive;Anti-interferon antibody negative;Anti-interferon antibody
positive;Anti-islet cell antibody positive;Antimitochondrial antibody positive;Anti-muscle
specific kinase antibody positive;Anti-myelin-associated glycoprotein antibodies
positive;Anti-myelin-associated glycoprotein associated polyneuropathy;Antimyocardial
antibody positive;Anti-neuronal antibody positive;Antineutrophil cytoplasmic antibody
increased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil cytoplasmic
antibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibody
increased;Antinuclear antibody positive;Antiphospholipid antibodies
positive;Antiphospholipid syndrome;Anti-platelet antibody positive;Anti-prothrombin
antibody positive;Antiribosomal P antibody positive;Anti-RNA polymerase III antibody
positive;Anti-saccharomyces cerevisiae antibody test positive;Anti-sperm antibody
positive;Anti-SRP antibody positive;Antisynthetase syndrome;Anti-thyroid antibody
positive;Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;AntiVGKC antibody positive;Anti-vimentin antibody positive;Antiviral prophylaxis;Antiviral
treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic
thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application site
thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass
thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site
stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis
Page 30
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000083
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 2
coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus
thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase
increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index
increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypical
benign partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmune
anaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blistering
disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinating
disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune
encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eye
disorder;Autoimmune haemolytic anaemia;Autoimmune heparin-induced
thrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmune
hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune
lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune
nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune
pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune
retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune
uveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatism
epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial
spondyloarthritis;Axillary vein thrombosis;Axonal and demyelinating
polyneuropathy;Axonal neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band
sensation;Basedow's disease;Basilar artery thrombosis;Basophilopenia;B-cell
aplasia;Behcet's syndrome;Benign ethnic neutropenia;Benign familial neonatal
convulsions;Benign familial pemphigus;Benign rolandic epilepsy;Beta-2 glycoprotein
antibody positive;Bickerstaff's encephalitis;Bile output abnormal;Bile output
decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin conjugated
increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase deficiency;Birdshot
chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline phosphatase
increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin unconjugated
increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood pressure
decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toe
syndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stem
thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis
mycoplasmal;Bronchitis viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;BuddChiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calcium
embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac
failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic
shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory
arrest;Cardio-respiratory distress;Cardiovascular insufficiency;Carotid arterial
embolus;Carotid artery thrombosis;Cataplexy;Catheter site thrombosis;Catheter site
vasculitis;Cavernous sinus thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement
embolism;Central nervous system lupus;Central nervous system vasculitis;Cerebellar artery
thrombosis;Cerebellar embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral
artery embolism;Cerebral artery thrombosis;Cerebral gas embolism;Cerebral
microembolism;Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinus
thrombosis;Cerebral venous thrombosis;Cerebrospinal thrombotic
Page 31
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000084
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 3
tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;ChildPugh-Turcotte score abnormal;Child-Pugh-Turcotte score
increased;Chillblains;Choking;Choking sensation;Cholangitis sclerosing;Chronic
autoimmune glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue
syndrome;Chronic gastritis;Chronic inflammatory demyelinating
polyradiculoneuropathy;Chronic lymphocytic inflammation with pontine perivascular
enhancement responsive to steroids;Chronic recurrent multifocal osteomyelitis;Chronic
respiratory failure;Chronic spontaneous urticaria;Circulatory collapse;Circumoral
oedema;Circumoral swelling;Clinically isolated syndrome;Clonic convulsion;Coeliac
disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic
anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen
disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1
decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement
factor C4 decreased;Complement factor decreased;Computerised tomogram liver
abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian
syndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenital
varicella infection;Congestive hepatopathy;Convulsion in childhood;Convulsions
local;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary artery
disease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypass
thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus
test positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19
immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial
nerve disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST
syndrome;Crohn's disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band
present;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous
sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine
release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute
inflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosis
postoperative;Deficiency of bile secretion;Deja vu;Demyelinating
polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis
herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes
mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membrane
reaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated
intravascular coagulation;Disseminated intravascular coagulation in newborn;Disseminated
neonatal herpes simplex;Disseminated varicella;Disseminated varicella zoster vaccine virus
infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex
syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop
attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with
burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolic
cerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic
stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis
allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis
haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post
immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine
ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter
pneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;Eosinophilic
Page 32
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000085
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 4
fasciitis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic
oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic
seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema
multiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disability
status scale score decreased;Expanded disability status scale score increased;Exposure to
communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye
swelling;Eyelid oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic
seizure;Fat embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile
neutropenia;Felty's syndrome;Femoral artery embolism;Fibrillary
glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal
dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor
hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes
mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test
decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase
increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset
non-motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpes
simplex;Genital herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis
membranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidly
progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency
syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2
gangliosidosis;Goodpasture's syndrome;Graft
thrombosis;Granulocytopenia;Granulocytopenia neonatal;Granulomatosis with
polyangiitis;Granulomatous dermatitis;Grey matter heterotopia;Guanase increased;GuillainBarre syndrome;Haemolytic anaemia;Haemophagocytic
lymphohistiocytosis;Haemorrhage;Haemorrhagic ascites;Haemorrhagic
disorder;Haemorrhagic pneumonia;Haemorrhagic varicella syndrome;Haemorrhagic
vasculitis;Hantavirus pulmonary infection;Hashimoto's
encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;HenochSchonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced
thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow
decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme
decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis
marker increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic
hypertrophy;Hepatic hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic
pain;Hepatic sequestration;Hepatic vascular resistance increased;Hepatic vascular
thrombosis;Hepatic vein embolism;Hepatic vein thrombosis;Hepatic venous pressure
gradient abnormal;Hepatic venous pressure gradient increased;Hepatitis;Hepatobiliary scan
abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase
inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes
ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex
cervicitis;Herpes simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes
simplex hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes
simplex meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex
oesophagitis;Herpes simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex
pneumonia;Herpes simplex reactivation;Herpes simplex sepsis;Herpes simplex
viraemia;Herpes simplex virus conjunctivitis neonatal;Herpes simplex visceral;Herpes virus
Page 33
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000086
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 5
infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection
neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster
meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising
retinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zoster
reactivation;Herpetic radiculopathy;Histone antibody positive;Hoigne's syndrome;Human
herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection
reactivation;Human herpesvirus 7 infection;Human herpesvirus 8
infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia
benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity
vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H
ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal
nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive
crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4
lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic
neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerve
paralysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immunemediated adverse reaction;Immune-mediated cholangitis;Immune-mediated
cholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediated
encephalopathy;Immune-mediated endocrinopathy;Immune-mediated enterocolitis;Immunemediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immunemediated hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated
myocarditis;Immune-mediated myositis;Immune-mediated nephritis;Immune-mediated
neuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated
renal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis;Immunoglobulin G4
related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion body
myositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infective
thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site
vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instillation
site thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous
dermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranial
pressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsic
factor antibody positive;IPEX syndrome;Irregular breathing;IRVAN syndrome;IVth nerve
paralysis;IVth nerve paresis;JC polyomavirus test positive;JC virus CSF test positive;Jeavons
syndrome;Jugular vein embolism;Jugular vein thrombosis;Juvenile idiopathic
arthritis;Juvenile myoclonic epilepsy;Juvenile polymyositis;Juvenile psoriatic
arthritis;Juvenile spondyloarthritis;Kaposi sarcoma inflammatory cytokine
syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosisprone diabetes mellitus;Kounis syndrome;Lafora's myoclonic epilepsy;Lambl's
excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal rheumatoid
arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LE
cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase
increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia
neonatal;Lewis-Sumner syndrome;Lhermitte's sign;Lichen planopilaris;Lichen planus;Lichen
sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function
test abnormal;Liver function test decreased;Liver function test increased;Liver
induration;Liver injury;Liver iron concentration abnormal;Liver iron concentration
Page 34
090177e196ea1800\Approved\Approved On: 30-A
pr-2021 09:26 (GMT)
FDA-CBER-2021-5683-0000087
BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 6
increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Liver
tenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratory
tract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepatic
cirrhosis;Lupus cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupus
hepatitis;Lupus myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupus
pleurisy;Lupus pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytic
hypophysitis;Lymphocytopenia neonatal;Lymphopenia;MAGIC syndrome;Magnetic
resonance imaging liver abnormal;Magnetic resonance proton density fat fraction
measurement;Mahler sign;Manufacturing laboratory analytical testing issue;Manufacturing
materials issue;Manufacturing production issue;Marburg's variant multiple
sclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocytic
enterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medical
device site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitis
herpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitis
herpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test
positive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesenteric
artery thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastatic
cutaneous Crohn's disease;Metastatic pulmonary
embolism;Microangiopathy;Microembolism;Microscopic polyangiitis;Middle East
respiratory syndrome;Migraine-triggered seizure;Miliary pneumonia;Miller Fisher
syndrome;Mitochondrial aspartate aminotransferase increased;Mixed connective tissue
disease;Model for end stage liver disease score abnormal;Model for end stage liver disease
score increased;Molar ratio of total branched-chain amino acid to tyrosine;Molybdenum
cofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathy
multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal
motor neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosis
relapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisystem
inflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia
gravis crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitis
transverse;Myocardial infarction;Myocarditis;Myocarditis post infection;Myoclonic
epilepsy;Myoclonic epilepsy and ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasal
herpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's disease;Neonatal
epileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpes
simplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic
fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudo
relapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronal
neuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosa
syndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenia
neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodular
vasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfective
encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupational
exposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocular
hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocular
vasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepatic
disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmic
herpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic

Link to this

Things to do with this request

Anyone:
New Zealand Police only: